Characteristics and Outcomes of Patients with Primary Central Nervous System Lymphoma
Keywords:
methotrexate, overall survival, primary central nervous system lymphoma, radiotherapy
Abstract
Background: The aim of the present retrospective study was to review the clinicopathological characteristics and outcomes of primary central nervous system lymphoma (PCNSL) cases at our institute. Methods: Patients diagnosed with PCNSL at our institute from August 2010 to May 2015 were evaluated. During the said period, a total of 14 cases were diagnosed with PCNSL. Results: Deep frontal lobe was the most common site of involvement while diffuse large B-cell lymphoma (DLBCL) was the most common histological pattern. 10 patients were treated with 3.0 g/m 2 methotrexate (MTX) intravenously concomitant with intraventricular 15 mg MTX and 2 patients were treated with radiotherapy (RT). Two of the patients died due to respiratory failure a short time after the treatment started. The median overall survival (OS) was 8 months (minimum: 1 months, maximum: 15 months) and the median OS was 12.42±13.20 months (min: 1 month, max: 48 months). Conclusion: As stated in the previous studies, MTX-based chemotherapy regimens are still the most effective treatment option in this patient population.
Downloads
- Article PDF
- TEI XML Kaleidoscope (download in zip)* (Beta by AI)
- Lens* NISO JATS XML (Beta by AI)
- HTML Kaleidoscope* (Beta by AI)
- DBK XML Kaleidoscope (download in zip)* (Beta by AI)
- LaTeX pdf Kaleidoscope* (Beta by AI)
- EPUB Kaleidoscope* (Beta by AI)
- MD Kaleidoscope* (Beta by AI)
- FO Kaleidoscope* (Beta by AI)
- BIB Kaleidoscope* (Beta by AI)
- LaTeX Kaleidoscope* (Beta by AI)
How to Cite
References
Chang-Hyun Lee, Kyu-Won Jung, Heon Yoo, Sohee Park, Seung Lee (2010) Epidemiology of Primary Brain and Central Nervous System Tumors in Korea. 48(2), 145. https://doi.org/10.3340/jkns.2010.48.2.145
Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W (2006) Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model. 24, 5711-5715.
Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A (2003) Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience. 21, 266-272.
Bessell EM, Hoang-Xuan K, Ferreri AJ, Reni M (2007) Primary central nervous system lymphoma: biological aspects and controversies in management. 43, 1141-1152.
Ekenel M, Deangelis LM (2007) Treatment of primary central nervous system lymphoma. 9, 271-282.
Gerstner E, Batchelor T (2007) Primary CNS lymphoma. 7, 689-700.
Jahnke K, Thiel E (2009) Treatment options for central nervous system lymphomas in immunocompetent patients. 9, 1497-1509.
Morris PG, Abrey LE (2009) Therapeutic challenges in primary CNS lymphoma. 8, 581-92.
Nina Kadan‐lottick, Maria Skluzacek, James Gurney (2002) Decreasing incidence rates of primary central nervous system lymphoma. 95(1), 193-202. https://doi.org/10.1002/cncr.10643
Dubuisson A, Kaschten B, Lénelle J, Martin D, Robe P, Fassotte MF (2004) Primary central nervous system lymphoma report of 32 cases and review of the literature. 107, 55-63.
Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D (2007) Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma. 25, 4730-4735.
Hormigo Gavrilovic IT, DeAngelis Yahalom J (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. 24, 4570-4.
Omuro AM, DeAngelis LM, Yahalom J, Abrey LE (2005) Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. 64, 69-74.
Abrey LE, Yahalom J, DeAngelis LM (2000) Treatment for Primary CNS Lymphoma: The Next Step. 18, 3144-3150.
D. Correa, L. DeAngelis, W. Shi, H. Thaler, A. Glass, L. Abrey (2004) Cognitive functions in survivors of primary central nervous system lymphoma. 62, 548-555.
J. Crossen, D. Garwood, E. Glatstein, E. Neuwelt (1994) Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. 12, 627-42.
L. Deangelis, F. Iwamoto (2006) An update on therapy of primary central nervous system lymphoma. 20, 1267-1285.
Bataille B, Delwail V, Menet E, Vandermarcq P, Ingrand P, Wager M (2000) Primary intracerebral malignant lymphoma: report of 248 cases. 92, 261-266.
U. Basso, A. Brandes (2002) Diagnostic advances and new trends for the treatment of primary central nervous system lymphoma. 38, 1298-1312.
Jaiswal AK, Mahapatra AK, Sharma MC (2004) Primary central nervous lymphoma presenting as bilateral cerebellopontine angle lesions: a rare case report. 11, 328-331.
Sarkar C, Sharma MC, Deb P, Singh R, Santosh V, Shankar SK (2005) Primary central nervous system lymphoma: A hospital based study of incidence and Clinicopathological feature from India (1980 -2003). 71, 199-204.
Ferreri AJ, Guerra E, Regazzi M, Pasini F, Ambrosetti A, Pivnik A (2004) Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. 90, 353-358.
Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J (2003) Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. 21, 2726-2731.
Plotkin SR, Batchelor TT (2001) Primary nervous-system lymphoma. 2, 354-365.
Blay JY, Conroy T, Chevreau C, Thyss A, Quesnel N, Eghbali H (1998) High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. 16, 864-871.
Published
2017-06-12
Issue
Section
License
Copyright (c) 2017 Authors and Global Journals Private Limited

This work is licensed under a Creative Commons Attribution 4.0 International License.